Announcements Trials

Browse Landscape

Phase

Phase 2 7 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1 CNS 1

Conditions

Melanoma 5 Neoplasm Metastasis 3 Colorectal Neoplasms 3 Solid Tumors Harboring a BRAF V600 Mutation 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Lung Neoplasms 1 Gastrointestinal Neoplasms 1 Disease Progression 1 Digestive System Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1 Advanced BRAF Mutant Cancers 1

Interventions

Temozolomide 26 Bevacizumab 14 Radiosurgery 12 Radiotherapy 9 pembrolizumab 8 Carboplatin 8 Trastuzumab 6 temsirolimus 5 Sirolimus 5 Erlotinib Hydrochloride 5 abemaciclib 4 Paclitaxel 4 Irinotecan 4 Capecitabine 4 tipifarnib 3 Sorafenib 3 Radiation 3 Mental Status and Dementia Tests 3 Ipilimumab 3 Everolimus 3 Aminolevulinic Acid 3 130-nm albumin-bound paclitaxel 3 tucatinib 2 pertuzumab 2 fludarabine 2 durvalumab 2 alovudine 2 alectinib 2 Vorinostat 2 Surgical Procedures, Operative 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Brain Neoplasms × encorafenib × Clear all

NCT06194929 2025-12-03

DETERMINE

University of Utah

Phase 1/2 Recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡